Teplizumab + Placebo
Phase 2/3Completed 1 views this week 0 watching💤 Quiet
Interest: 38/100
38
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Type 1 Diabetes Mellitus
Conditions
Type 1 Diabetes Mellitus
Trial Timeline
Oct 1, 2006 → Aug 1, 2011
NCT ID
NCT00385697About Teplizumab + Placebo
Teplizumab + Placebo is a phase 2/3 stage product being developed by Eli Lilly for Type 1 Diabetes Mellitus. The current trial status is completed. This product is registered under clinical trial identifier NCT00385697. Target conditions include Type 1 Diabetes Mellitus.
What happened to similar drugs?
20 of 20 similar drugs in Type 1 Diabetes Mellitus were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
15
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00385697 | Phase 2/3 | Completed |
Competing Products
20 competing products in Type 1 Diabetes Mellitus